期刊文献+

多发性骨髓瘤患者中性粒细胞与淋巴细胞比值与预后相关性分析 被引量:7

Correlation between neutrophil to lymphocyte ratio and the prognosis in patients with multiple myeloma
下载PDF
导出
摘要 目的:研究外周血中中性粒细胞与淋巴细胞比值(NLR)在多发性骨髓瘤(MM)患者预后中的价值。方法:回顾性分析88例初诊MM患者的临床资料,将MM患者分为高NLR组与低NLR组,分析两组患者在血红蛋白(Hb)、血清钙离子(Ca)、血清β2微球蛋白(β2-MG)、血清白蛋白(ALB)、血清肌酐(Cr)、国际分期标准(ISS)和总体生存期(OS)方面的差异。结果:与低NLR组相比,高NLR组血清β2-MG偏高、Cr偏高、Ca偏高、ISS分期偏晚、OS短,差异均有统计学意义(P<0.05)。结论:MM患者外周血中NLR升高提示预后不良,NLR与血清β2-MG、Cr等指标相结合,对于MM患者的预后评估有重要的意义。 Objective: To study the value of neutrophil to lymphocyte ratio(NLR) in the prognosis of patients with multiple myeloma(MM). Methods: The clinical data of 88 newly diagnosed MM patients were analyzed retrospectively.MM patients were divided into high NLR group and low NLR group.The hemoglobin(Hb),serum calcium(Ca),serum β2 microglobulin,albumin(ALB),serum creatinine(Cr),international staging criteria(ISS) and overall survival(OS) were analyzed. Results: There were statistically significant differences in the expression of β2-MG,Ca and Cr between high NLR group and low NLR group( P〈0.05).There were also statistically significant differences in the ISS,over survival between high NLR group and low NLR group( P〈0.05). Conclusion: NLR combination with β2-MG,Cr and Ca can provide important value to evaluate the prognosis of MM patients.
作者 唐元艳 张利铭 张江召 熊涛 梁艳 余卓君 刘荟敏 刘敏 黄知平 Tang Yuanyan;Zhang Liming;Zhang Jiangzhao;Xiong Tao;Liang Yan;Yu Zhuojun;Liu Huimin;Liu Min;Huang Zhiping(Department of Hematology,Jingzhou Central Hospital,Affiliated to Tongji Medical College of Huazhong Science and Technology University,Hubei Jingzhou 434020,China)
出处 《现代肿瘤医学》 CAS 2018年第12期1899-1901,共3页 Journal of Modern Oncology
关键词 多发性骨髓瘤 中性粒细胞与淋巴细胞比值 预后 multiple myeloma neutrophil to lymphocyte ratio(NLR) prognosis
  • 相关文献

参考文献2

二级参考文献40

  • 1Attal M, Lauwers Cances V, Marit G, et al. Lenalidomide mainte- nance after stem - cell transplantation for multiple myeloma [ J ]. N Eng J Med,2012,366 (19) : 1782 - 1791. 被引量:1
  • 2McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem - cell transplantation for multiple myeloma [ J ]. N Eng J Med,2012,366 (19) : 1770 - 1781. 被引量:1
  • 3Lohr JG, Stojanov P, Carter SL,et al. Widespread genetic heteroge- neity in multiple myeloma : Implications for targeted therapy [ J ]. Cancer Ce11,2014,25 ( 1 ) :91 - 101. 被引量:1
  • 4Scheid C, Sonneveld P, Schmidt Wolf I GH, et al. Bortezomib before and after autologous stem cell transplantation overcomes the nega- tive prognostic impact of renal impairment in newly diagnosed mul- tiple myeloma:A subgroup analysis from the HOVON -65/GMMG - HD4 trial [ J]. Haematologica,2014,99 ( 1 ) : 148 - 154. 被引量:1
  • 5Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open - label study of siltuximab, an anti - IL - 6 monoclonal antibody, in pa- tients with B - cell non - Hodgkin lymphoma, multiple myeloma, or castleman disease [ J ]. Clin Cancer Res, 2013,19 ( 13 ) : 3659 - 3670. 被引量:1
  • 6Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma [ J ]. Nature Rev Nephro1,2012,8 ( 1 ) :43 - 51. 被引量:1
  • 7Ramachandran I, Condamine T, Gabrilovich D, et al. Bone marrow myeloid cells promote multiple myeloma chemoresistance by DNA mediated signaling[ J]. Cancer Res ,2014,74 ( 19 ) : 164. 被引量:1
  • 8Roussel M, Lauwers Cances V, Robillard N, et al. Front - line transplantation program with lenalidomide, bortezomib, and dexam- ethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase Ⅱ study by the intergroupe francophone du my~lome [ J ]. J Clin Onco1,2014,32 (25) :2712 - 2717. 被引量:1
  • 9Agarwal JR, Wang Q, Tanno T, et al. Activation of liver x receptors inhibits hedgehog signaling, clonogenic growth, and self - renewal in multiple myeloma[ J]. Mol Cancer Therap,2014,13 (7) : 1873 - 1881. 被引量:1
  • 10Chanan - kena A, Miller KC. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma [ J ]. Leukemia & lymphoma,2005,46:1103 -1104. 被引量:1

共引文献13

同被引文献63

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部